NCT04433156 is a Phase 2 clinical trial of Bortezomib in Marginal Zone Lymphoma, sponsored by Henan Cancer Hospital.

Who is sponsoring NCT04433156?

NCT04433156 is sponsored by Henan Cancer Hospital.

What drugs are being tested in NCT04433156?

Interventions in NCT04433156: Bortezomib, Rituximab, Epirubicin, Cyclophosphamide, Prednisone.

What condition does NCT04433156 study?

NCT04433156 studies Marginal Zone Lymphoma.

Is NCT04433156 still recruiting?

NCT04433156 is currently completed. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT04433156

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Completed Phase 2 Last updated 9 April 2026

What this trial tests

Phase 2 trial testing Bortezomib in Marginal Zone Lymphoma in 26 participants. Completed in 31 March 2026.

Timeline

22 April 2020

Primary endpoint
31 July 2025

31 March 2026

Quick facts

Lead sponsor	Henan Cancer Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	22 April 2020
Primary completion	31 July 2025
Estimated completion	31 March 2026
Sites	1 location across China

Drugs / interventions tested

Bortezomib (bortezomib) — full drug profile →
Rituximab — full drug profile →
Epirubicin (EPIRUBICIN) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Prednisone (prednisone) — full drug profile →

Conditions studied

Marginal Zone Lymphoma — all drugs for Marginal Zone Lymphoma →

Sponsor

Henan Cancer Hospital

Who can join

Adults 18 to 70, any sex, with Marginal Zone Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Bortezomib

Trials testing the same drug.

NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07224672 — A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an · Phase 2 · not yet recruiting
NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting

Other recruiting trials for Marginal Zone Lymphoma

Currently open trials in the same condition.

NCT06796998 — Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) · Phase 2 · recruiting
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
NCT06860880 — Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · NA · recruiting
NCT06636175 — 64Cu-LLP2A for Imaging Hematologic Malignancies · EARLY_PHASE1 · recruiting
NCT06563596 — Epco, Zanu, Ritux for R/R FL or MZL · Phase 2 · recruiting

Other Henan Cancer Hospital trials

Trials by the same sponsor.

NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04433156 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04433156.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing